与事件相关的潜在在阿尔茨海默病中的应用:系统的审查和分析
Qian Liang1, Zhilin Chen1, Xiaohui Tang1
1Department of Neurology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Frontiers in aging neuroscience
|May 19, 2025
概括
早期发现阿尔茨海默病 (AD) 是至关重要的. 本研究回顾了事件相关潜力 (ERP) 如何帮助AD诊断,监测和理解其病理.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 生物医学工程 生物医学工程
背景情况:
- 阿尔茨海默病 (AD) 的患病率正在上升,这对公众健康构成了重大挑战.
- 早期发现认知障碍对于有效的治疗干预来减缓AD进展至关重要.
- 与事件相关的潜能 (ERP) 提供了一种非侵入性,客观的方法来评估与认知过程相关的大脑活动.
研究的目的:
- 在阿尔茨海默病的背景下全面评估ERP的实用性.
- 探索不同ERP组件在AD诊断和监测中的作用.
- 审查ERP在阿尔茨海默病病理机制研究中的应用.
主要方法:
- 在PubMed,Web of Science和Scopus数据库中进行系统的文献搜索.
- 包括和分析有关ERP和阿尔茨海默病的相关研究.
- 探索各种ERP组件及其诊断和预后价值.
主要成果:
- 在早期诊断阿尔茨海默病方面,ERP具有显著的潜力.
- 特定的ERP组件与阿尔茨海默病患者的疾病进展和认知衰退相关.
- 对ERP的分析为AD的潜在神经病理机制提供了洞察力.
结论:
- ERP是诊断和监测阿尔茨海默病的一个有价值的工具.
- 对ERP应用程序的进一步研究可以加强对AD的早期检测和治疗策略.
- ERP为了解和管理阿尔茨海默病提供了一种有希望的非侵入性方法.
更多相关视频
07:03Evaluation of Hemisphere Lateralization with Bilateral Local Field Potential Recording in Secondary Motor Cortex of Mice
Published on: July 31, 2019
6.7K
09:52How to Find Effects of Stimulus Processing on Event Related Brain Potentials of Close Others when Hyperscanning Partners
Published on: May 31, 2018
7.7K
相关概念视频
01:26Alzheimer's Disease: Overview
399
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
399
01:22Alzheimer's Disease: Treatment
137
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
137